We investigated the immunocorrective and clinical effect in 75 rheumatoid patients treated with intravenous laser blood irradiation. A relation between the positive immunotropic (as well as therapeutic) effect and the pre-existent immune status of each patient was revealed. A well-defined effect was found in patients with a low level of CIC and a normal count of functional-competent T-cells. ILIB provided some symptomatic but unstable relief in patients with a high level of CIC and a high functional activity of T-lymphocytes. There was no effect in patients with a high level of CIC and decreased number of lymphocytes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0928-4680(00)00059-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design.
Arch Cardiovasc Dis
December 2024
Department of pharmacology, Sorbonne Université, Inserm, CIC-1901, AP-HP, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
Background: Immune checkpoint inhibitor (ICI)-induced myocarditis is a life-threatening adverse drug reaction. Abatacept (a CTLA-4-immunoglobulin fusion protein) has been proposed as a compassionate-use treatment for ICI myocarditis (in combination with corticosteroids and ruxolitinib) but no clinical trial has yet been performed. The abatacept dose can be adjusted using real-time assessment of its target, the CD86 receptor occupancy on circulating monocytes (CD86RO).
View Article and Find Full Text PDFSudden deaths in infancy and pesticide exposure: a systematic review.
Environ Res
December 2024
Univ Rennes, CHU Rennes, Inserm, Irset (Research Institute for Environmental & Occupational Health) UMR 1085, Rennes, France.
Sudden unexpected deaths in infancy (SUDI) is defined as the unexpected death of an infant in the first year of life, including explained and unexplained death (SIDS). Risk factors, such as sleeping position and passive smoking, have been identified but few studies have addressed the influence of exposure to chemicals in the environment. Pesticides are ubiquitous but little is known about their impact on infant mortality.
View Article and Find Full Text PDFSafety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.
EBioMedicine
December 2024
Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Section for Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway. Electronic address:
Background: The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher incidence of serious adverse events (SAEs) among SARS-CoV-2-vaccinated participants who had received baricitinib. This sub-study aimed to investigate whether vaccination influences the safety profile of baricitinib in patients with severe COVID-19.
View Article and Find Full Text PDFHuman brain aging is associated with dysregulation of cell type epigenetic identity.
Geroscience
December 2024
Department of Ecology, Evolution, and Marine Biology, Department of Molecular, Cellular, and Cell Biology, Neuroscience Research Institute, University of California, Santa Barbara, CA, 93106, USA.
Significant links between aging and DNA methylation are emerging from recent studies. On the one hand, DNA methylation undergoes changes with age, a process termed as epigenetic drift. On the other hand, DNA methylation serves as a readily accessible and accurate biomarker for aging.
View Article and Find Full Text PDFEffect of oral nintedanib vs placebo on epistaxis in hereditary hemorrhagic telangiectasia: the EPICURE multicenter randomized double-blind trial.
Angiogenesis
December 2024
Service de Génétique et centre de reference de la maladie de Rendu-Osler, Hôpital Femme-Mère-Enfants, Hospices Civils de Lyon, Bron, France.
Epistaxis greatly affects patients with hereditary hemorrhagic telangiectasia (HHT). Although few systemic treatment exist, nintedanib, is a good candidate thanks to its anti-angiogenic activity. Our main objective was to evaluate the efficacy of oral nintedanib on epistaxis duration in HHT patients with moderate to severe epistaxis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!